A novel variant in the DSE gene leads to Ehlers‐Danlos musculocontractural type 2 ( mcEDS‐ DSE ) in a Pakistani family

2021 ◽  
Author(s):  
Ikram Ullah ◽  
Muhammad Aamir ◽  
Muhammad Ilyas ◽  
Akmal Ahmed ◽  
Musharraf Jelani ◽  
...  
Author(s):  
Paula Sienes Bailo ◽  
José Luis Bancalero Flores ◽  
Raquel Lahoz Alonso ◽  
María Santamaría González ◽  
Alex Gutiérrez Dalmau ◽  
...  

ABSTRACT Objectives Patients with Alport syndrome develop progressive kidney function deterioration, sensorineural hearing loss, and ocular abnormalities. This condition is caused by mutations in COL4A5 (X-linked inheritance), COL4A3 and COL4A4 (autosomal dominant or recessive inheritance), and encoding type IV collagen α3, α4, and α5, respectively. If left untreated, clinical symptoms progress from microscopic hematuria to proteinuria, progressive kidney failure, and end-stage kidney disease. At present, kidney transplantation is the only effective approach. Next-generation sequencing is the method of choice for the diagnosis of this condition. Case presentation We report the case of a young man with chronic kidney disease who eventually underwent transplantation. Molecular testing made it possible to determine the etiology of his clinical symptoms and autosomal recessive Alport syndrome type 2. The patient was found to be a compound heterozygote for two missense variants (trans configuration) in the COL4A3 gene: A likely pathogenic variant c.4981C>T (p.Arg1661Cys) in exon 52 inherited from the mother (described elsewhere), and another variant of uncertain significance, c.943G>A (p.Gly315Ser), in exon 17 inherited from the father that has not been previously reported in the literature or found in relevant databases. Conclusions Following genetic confirmation, genetic counseling was provided to the patient and his direct relatives.


Diabetes ◽  
2002 ◽  
Vol 51 (3) ◽  
pp. 880-883 ◽  
Author(s):  
D. Mentuccia ◽  
L. Proietti-Pannunzi ◽  
K. Tanner ◽  
V. Bacci ◽  
T. I. Pollin ◽  
...  

Author(s):  
Farina Hanif ◽  
Qurat-ul-Ain Amir ◽  
Washdev Washdev ◽  
Fareena Bilwani ◽  
Shabana Usman Simjee ◽  
...  

Author(s):  
Tomoya Kubota ◽  
Shin Nabatame ◽  
Ruka Sato ◽  
Manami Hama ◽  
Ujiakira Nishiike ◽  
...  

2020 ◽  
Vol 41 (4) ◽  
pp. 377-380
Author(s):  
Tariq Alzahem ◽  
Abrar K. Alsalamah ◽  
Marco Mura ◽  
Sulaiman M. Alsulaiman
Keyword(s):  

2021 ◽  
pp. 100334
Author(s):  
Lorenzo Verriello ◽  
Paola Carrera ◽  
Giada Pauletto ◽  
Andrea Bernardini ◽  
Mariarosaria Valente ◽  
...  

Author(s):  
Cigdem Seher Kasapkara ◽  
Asburce Olgac ◽  
Mustafa Kilic ◽  
Liesbeth Keldermans ◽  
Gert Matthijs ◽  
...  

Abstract Objectives Congenital disorders of glycosylation (CDGs) are a group of genetic disorders due to hypoglycosylation of proteins and lipids. A type I pattern is associated with defects in glycan assembly and transfer (CDG-I; cytosol; and endoplasmic reticulum defects), a type II pattern is seen in processing defects of the Golgi apparatus. MAN1B1-CDG is an autosomal recessive CDG-II due to mutations in the α 1,2-mannosidase gene (MAN1B1), mainly characterized by psychomotor disability, facial dysmorphism, truncal obesity, and hypotonia. Case presentation Three patients (two males and one female), with MAN1B1-CDG who had elevated transaminase levels are presented. All patients had presented due to dysmorphic and neurological findings and hypertransaminasemia was remarkable. A type 2 pattern was found on serum transferrin isoelectrofocusing analysis of the presented cases. MAN1B1-CDG was confirmed by genetic analysis. Conclusions Although the cause of the increased serum transaminase levels in the present patients is not clear, no evidence for an infection or underlying liver pathology could be identified. In order to know if this is a consistent feature, we suggest measuring serum transaminase levels regularly in MAN1B1-CDG patients.


2021 ◽  
Vol 94 ◽  
pp. 8-12
Author(s):  
Shumaila Zulfiqar ◽  
Muhammad Tariq ◽  
Shafaq Ramzan ◽  
Ayaz Khan ◽  
Muhammad Sher ◽  
...  

2018 ◽  
Vol 2018 ◽  
pp. 1-3
Author(s):  
Sean Lance ◽  
Stuart Mossman ◽  
Gemma Poke

Episodic ataxia is a heterogenous group of uncommon neurological disorders characterised by recurrent episodes of vertigo, dysarthria, and ataxia for which a variety of different genetic variations have been implicated. Episodic ataxia type two (EA2) is the most common and also has the largest number of identified causative genetic variants. Treatment with acetazolamide is effective in improving symptoms, so accurate diagnosis is essential. However, a large proportion of patients with EA2 have negative genetic testing. We present a patient with a typical history of EA2 who had a novel variant in the CACNA1A gene not previously described. Report of such variations is important in learning more about the disease and improving diagnostic yield for the patient.


Sign in / Sign up

Export Citation Format

Share Document